FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
16 letters match. Newest first.
-
DrugsShenzhen Benliju Biotech Co., Ltd.
FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.
High risk -
DrugsLGM Pharma Solutions, LLC
FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.
High risk -
DrugsSanrace Biotechnology Co., Ltd.
FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.
High risk -
DevicesOlympus Medical Systems Corporation
FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsHappy Farm Botanicals, Inc.
Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsTianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
High risk -
DrugsWoodbine Products Company Inc.
Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
High risk -
DrugsDabur India Limited
FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
High risk -
DrugsABS Corporation
ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
High risk -
DrugsAHC Products, Inc.
AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
High risk -
DrugsIsland Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsJW Nutritional LLC
FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.
High risk -
DevicesAvertix Medical, Inc.
FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.
High risk